1. Home
  2. LX vs BDTX Comparison

LX vs BDTX Comparison

Compare LX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LexinFintech Holdings Ltd.

LX

LexinFintech Holdings Ltd.

HOLD

Current Price

$0.50

Market Cap

102.7M

Sector

Finance

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

SELL

Current Price

$1.34

Market Cap

104.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LX
BDTX
Founded
2013
2014
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.7M
104.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
LX
BDTX
Price
$0.50
$1.34
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$2.13
★ $11.00
AVG Volume (30 Days)
★ 843.4K
688.1K
Earning Date
12-01-2026
11-10-2026
Dividend Yield
★ 71.14%
N/A
EPS Growth
N/A
★ 130.71
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.08
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$1.35
52 Week High
$3.88
$3.97

Technical Indicators

Market Signals
Indicator
LX
BDTX
Relative Strength Index (RSI) 31.26 33.86
Support Level N/A N/A
Resistance Level $0.74 $1.94
Average True Range (ATR) 0.05 0.14
MACD -0.01 -0.03
Stochastic Oscillator 1.33 3.08

Price Performance

Historical Comparison
LX
BDTX

About LX LexinFintech Holdings Ltd.

LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: